Causal Flows are statistically significant links between putative causal events (somatic mutations, copy number variations, chromosomal translocations, etc.) and the activity levels of regulators and regulons. In the causal flow, a mutation may causally activate or deactivate a downstream regulator which then might up- down-regulates a regulon that contains genes with similar expression profiles and binding sites.
Causal Mechanistic Flows regulated by Mutation NUP210L_code_potential_somatic
| ID | Mutation | Role | Regulator | Role | Regulon | # downstream regulons | # diffexp regulons | Drugs |
|---|---|---|---|---|---|---|---|---|
| CMF-05004 | NUP210L | up-regulates | POU3F3 | represses | R-2632 | 19 | 5 | Drugs (3) |
| CMF-05008 | NUP210L | up-regulates | POU3F3 | represses | R-2620 | 19 | 5 | Drugs (14) Regulator Drugs (0)Regulon Drugs (14)DICHLORPHENAMIDE, ALEPLASININ, SULTHIAME, ACETAZOLAMIDE, CILENGITIDE, CG250 177LU, GIRENTUXIMAB, CG250 111IN, INTETUMUMAB, COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, OCRIPLASMIN, ACETAZOLAMIDE SODIUM, VESENCUMAB, ABITUZUMAB |
| CMF-05009 | NUP210L | up-regulates | FOXD3 | represses | R-578 | 25 | 4 | Drugs (5) |
| CMF-05011 | NUP210L | up-regulates | FOXD3 | represses | R-572 | 25 | 4 | Drugs (11) Regulator Drugs (0)Regulon Drugs (11)SULTHIAME, CILENGITIDE, SENICAPOC, DKN-01, CG250 177LU, GIRENTUXIMAB, CG250 111IN, INTETUMUMAB, TOSEDOSTAT, BHQ-880, ABITUZUMAB |
| CMF-05014 | NUP210L | down-regulates | MAF | activates | R-185 | 19 | 5 | Drugs (1) |
| CMF-05016 | NUP210L | down-regulates | MAF | activates | R-189 | 19 | 5 | Drugs (0) Regulator Drugs (0)Regulon Drugs (0) |
| CMF-05017 | NUP210L | down-regulates | MAF | activates | R-183 | 19 | 5 | Drugs (4) |
| CMF-05018 | NUP210L | down-regulates | MAF | activates | R-179 | 19 | 5 | Drugs (6) Regulator Drugs (0)Regulon Drugs (6)DINOPROSTONE, CR-6086, GRAPIPRANT, RIVENPROST, DIQUAFOSOL, DIQUAFOSOL TETRASODIUM |
| CMF-05022 | NUP210L | down-regulates | ATF5 | activates | R-358 | 14 | 3 | Drugs (3) |
| CMF-05023 | NUP210L | down-regulates | ATF5 | activates | R-365 | 14 | 3 | Drugs (6) Regulator Drugs (0)Regulon Drugs (6)EDASALONEXENT, L19IL2, AS-1409, L19TNFA, L19SIP 131I, OCRIPLASMIN |
| CMF-05028 | NUP210L | down-regulates | GATA6 | activates | R-1256 | 18 | 3 | Drugs (5) Regulator Drugs (0)Regulon Drugs (5)MEDI-8968, ANAKINRA, AMG-108, COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, OCRIPLASMIN |
| CMF-05029 | NUP210L | down-regulates | GATA6 | activates | R-1258 | 18 | 3 | Drugs (0) Regulator Drugs (0)Regulon Drugs (0) |
| CMF-05033 | NUP210L | down-regulates | ELF4 | activates | R-3010 | 20 | 4 | Drugs (9) Regulator Drugs (0)Regulon Drugs (9)SULTHIAME, CILENGITIDE, SENICAPOC, CG250 177LU, GIRENTUXIMAB, CG250 111IN, INTETUMUMAB, TOSEDOSTAT, ABITUZUMAB |
| CMF-05034 | NUP210L | down-regulates | ELF4 | activates | R-3028 | 20 | 4 | Drugs (2) |
| CMF-05043 | NUP210L | down-regulates | ELF3 | activates | R-3695 | 14 | 2 | Drugs (2) |
| CMF-34811 | NUP210L | up-regulates | hsa-mir-9 | represses | R-2053 | 25 | 20 | Drugs (9) Regulator Drugs (0)Regulon Drugs (9)DICHLORPHENAMIDE, ALEPLASININ, SULTHIAME, ACETAZOLAMIDE, COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, OCRIPLASMIN, TOSEDOSTAT, ACETAZOLAMIDE SODIUM, VESENCUMAB |
| CMF-34812 | NUP210L | up-regulates | hsa-mir-9 | represses | R-171 | 25 | 20 | Drugs (2) |
| CMF-34813 | NUP210L | up-regulates | hsa-mir-9 | represses | R-189 | 25 | 20 | Drugs (0) Regulator Drugs (0)Regulon Drugs (0) |
| CMF-34814 | NUP210L | up-regulates | hsa-mir-9 | represses | R-274 | 25 | 20 | Drugs (2) |
| CMF-34815 | NUP210L | up-regulates | hsa-mir-9 | represses | R-307 | 25 | 20 | Drugs (2) |
| CMF-34816 | NUP210L | up-regulates | hsa-mir-9 | represses | R-411 | 25 | 20 | Drugs (2) |
| CMF-34817 | NUP210L | up-regulates | hsa-mir-9 | represses | R-2489 | 25 | 20 | Drugs (2) |
| CMF-34818 | NUP210L | up-regulates | hsa-mir-9 | represses | R-2605 | 25 | 20 | Drugs (2) |
| CMF-34819 | NUP210L | up-regulates | hsa-mir-9 | represses | R-572 | 25 | 20 | Drugs (11) Regulator Drugs (0)Regulon Drugs (11)SULTHIAME, CILENGITIDE, SENICAPOC, DKN-01, CG250 177LU, GIRENTUXIMAB, CG250 111IN, INTETUMUMAB, TOSEDOSTAT, BHQ-880, ABITUZUMAB |
| CMF-34820 | NUP210L | up-regulates | hsa-mir-9 | represses | R-646 | 25 | 20 | Drugs (15) Regulator Drugs (0)Regulon Drugs (15)ALEPLASININ, SULTHIAME, CILENGITIDE, SENICAPOC, DKN-01, CG250 177LU, GIRENTUXIMAB, CG250 111IN, INTETUMUMAB, COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, OCRIPLASMIN, TOSEDOSTAT, BHQ-880, VESENCUMAB, ABITUZUMAB |
| CMF-34821 | NUP210L | up-regulates | hsa-mir-9 | represses | R-3010 | 25 | 20 | Drugs (9) Regulator Drugs (0)Regulon Drugs (9)SULTHIAME, CILENGITIDE, SENICAPOC, CG250 177LU, GIRENTUXIMAB, CG250 111IN, INTETUMUMAB, TOSEDOSTAT, ABITUZUMAB |
| CMF-34822 | NUP210L | up-regulates | hsa-mir-9 | represses | R-3028 | 25 | 20 | Drugs (2) |
| CMF-34823 | NUP210L | up-regulates | hsa-mir-9 | represses | R-1091 | 25 | 20 | Drugs (0) Regulator Drugs (0)Regulon Drugs (0) |
| CMF-34824 | NUP210L | up-regulates | hsa-mir-9 | represses | R-1457 | 25 | 20 | Drugs (2) |
| CMF-34825 | NUP210L | up-regulates | hsa-mir-9 | represses | R-3695 | 25 | 20 | Drugs (2) |
| CMF-34826 | NUP210L | up-regulates | hsa-mir-9 | represses | R-1847 | 25 | 20 | Drugs (2) |
| CMF-34827 | NUP210L | up-regulates | hsa-mir-9 | represses | R-467 | 25 | 20 | Drugs (5) |
| CMF-34828 | NUP210L | up-regulates | hsa-mir-9 | represses | R-3138 | 25 | 20 | Drugs (5) |
| CMF-34829 | NUP210L | up-regulates | hsa-mir-9 | represses | R-1168 | 25 | 20 | Drugs (7) Regulator Drugs (0)Regulon Drugs (7)EDASALONEXENT, L19IL2, AS-1409, L19TNFA, L19SIP 131I, COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, OCRIPLASMIN |
| CMF-34830 | NUP210L | up-regulates | hsa-mir-9 | represses | R-3758 | 25 | 20 | Drugs (7) Regulator Drugs (0)Regulon Drugs (7)EDASALONEXENT, L19IL2, AS-1409, L19TNFA, L19SIP 131I, COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, OCRIPLASMIN |